30Jun 2022
Effectiveness, safety and treatment adherence of biosimilar follow‐on insulin in diabetes management

Effectiveness, safety and treatment adherence of biosimilar follow‐on insulin in diabetes management

To assess the change in HbA1c after initiation of biosimilar follow‐on insulin (Basaglar) or reference insulin (Lantus) among patients with type 2 diabetes. The study also compared treatment adherence, safety events and costs at 1 year after initiation of insulin. In patients with type 2 diabetes, Basaglar provided similar glycaemic control compared with Lantus, had a similar safety profile and lower drug costs, and showed more favourable adherence.

  • #endo-diabetology

Like

Save

Share